Avon Products (NYSE:AVP) issued its quarterly earnings results on Wednesday. The company has a one year low of $29.61 and a one year high of $53.83. This represents a 57.89% change for the EPS reported for the same quarter in the prior year. The rating is an average of the various different ratings given by analysts and brokers to Avon Products Incorporated, and then averaged into one rating by a team of analysts at Zacks in Chicago, Illinois. The webcast can be accessed via the Investors & Media section of XOMA’s website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on February 5, 2016. The company had reported a profit of $91.4 million, or 21 cents per share, a year earlier. Deutsche Bank lowered their price target on shares of Avon Products from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, September 15th. Its current ratio was 2.70 while its shares were below its 50 days simple moving average with -12.22%. The stock has a 50-day moving average of $3.72 and a 200-day moving average of $5.67.
Advertisement
Additionally, Avon Products Incorporated now has a market capitalization of 1.88B. Earnings per share were -0.81. Among the 5 analysts who were surveyed, the consensus expectation for quarterly sales had been 1804.906. Citigroup Inc. dropped their price objective on shares of Avon Products from $6.00 to $4.00 and set a “neutral” rating on the stock in a report on Monday, September 14th. The stock showed a negative performance of 3.45% in the recent trading session.
Advertisement
Avon Products, Inc.is a producer and marketer of beauty and related products. The Company’s offers its products under two product categories: Beauty and Fashion & Home. Beauty consists of color cosmetics, fragrances, skin care and personal care. The business ‘s segments are – based on geographic businesses and include commercial business units and Asia Pacific. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company has sales operations in 60 nations and territories, including America, and distributed its products in territories and 41 other nations.
